Close Menu

In the wake of safety questions over GlaxoSmithKline's Avandia, FDA is recommending more rigorous testing of diabetes drugs for heart attack and stroke risk. The new recommendations are effective immediately, reports the Wall Street Journal, and they suggest that clinical trials should be redesigned with heart attack and stroke risk assessment in mind, and that any cardiovascular events that occur during the trial should be reviewed by independent, blinded cardiologists.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Newsweek discusses the privacy issues raised by digital medicine.

A group of statisticians wants to eliminate researchers' reliance on 'statistical significance,' according to NPR.

In Nature this week: genetic analysis of Anatolian farmers, cotton genome analysis, and more.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.